Back

Answers in CME Inc. (AiCME)

  • Breast Neoplasms

Guidance on Menopause-Related VMS Management: A Focus on NK-Targeted Treatment Options

This enduring dialogue showcases a discussion of two experts and a patient perspective. The activity aims to improve clinicians ability to identify appropriate candidates and integrate VMS-related options targeting neurokinin (NK) receptor therapies associated with menopause or breast cancer treatment. As a result of this activity, learners should be better able to: 1. Identify the impact and burden of VMS as a consequence of menopause; 2. Outline the clinical rationale for novel therapeutic approaches to manage menopause-related VMS; 3. Evaluate the efficacy and safety of novel NK-targeted therapies for treating menopause-related VMS; and, 4. Implement patient-centered clinical approaches to improve outcomes for patients experiencing menopause-related VMS. Learners have access to downloadable materials for use in clinical practice.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.5 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Pricing

Free

Reported to ACCME by the provider

  • Microlearning
  • Credit · Up to 0.5 credits
  • Commercial Support
  • Released
    Mar 30, 2026
  • Last day to claim credit
    Mar 30, 2027 6 months left